Kwality Pharmaceuticals Management

Management criteria checks 2/4

Kwality Pharmaceuticals' CEO is Ramesh Arora, appointed in Jan 2016, has a tenure of 8.33 years. directly owns 26.9% of the company’s shares, worth ₹1.39B. The average tenure of the management team and the board of directors is 8.3 years and 8.4 years respectively.

Key information

Ramesh Arora

Chief executive officer

₹5.1m

Total compensation

CEO salary percentage	n/a
CEO tenure	8.3yrs
CEO ownership	26.9%
Management average tenure	8.3yrs
Board average tenure	8.4yrs

Recent management updates

Recent updates

CEO

Ramesh Arora (69 yo)

8.3yrs

Tenure

₹5,100,000

Compensation

Mr. Ramesh Arora has been the Managing Director and Executive Director of Kwality Pharmaceuticals Limited since January 16, 2016 and May 4, 1983 respectively. Mr. Arora has more than 3 decades of experienc...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ramesh Arora	MD & Director	8.3yrs	₹5.10m	26.9% ₹ 1.4b
Aditya Arora	CFO & Whole Time Director	8.3yrs	₹3.60m	11.95% ₹ 619.4m
Ajay Arora	Whole Time Director	no data	₹5.10m	13.59% ₹ 704.5m
Anju Arora	Whole Time Director	no data	₹2.10m	1.31% ₹ 67.7m
Geeta Arora	Whole Time Director	no data	₹2.10m	1.07% ₹ 55.7m
Gurpreet Kaur	Company Secretary & Compliance Officer	4.8yrs	no data	no data
Shankar Dayal	Chief Domestic Sales Officer	no data	no data	no data

8.3yrs

Average Tenure

54yo

Average Age

Experienced Management: 539997's management team is seasoned and experienced (8.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ramesh Arora	MD & Director	41yrs	₹5.10m	26.9% ₹ 1.4b
Aditya Arora	CFO & Whole Time Director	8.6yrs	₹3.60m	11.95% ₹ 619.4m
Ajay Arora	Whole Time Director	28.8yrs	₹5.10m	13.59% ₹ 704.5m
Anju Arora	Whole Time Director	13.6yrs	₹2.10m	1.31% ₹ 67.7m
Geeta Arora	Whole Time Director	13.6yrs	₹2.10m	1.07% ₹ 55.7m
Kiran Verma	Non-Executive Independent Director	8.3yrs	₹175.00k	no data
Pankaj Takkar	Non-Executive Independent Director	8.3yrs	₹139.00k	0.029% ₹ 1.5m
Ravi Singh	Non-Executive Independent Director	8.3yrs	₹27.00k	no data
Kartik Kapur	Independent Director	3.3yrs	₹25.00k	no data
Prashanth Vellanki	Non-Executive & Independent Director	1.2yrs	no data	no data

8.4yrs

Average Tenure

51yo

Average Age

Experienced Board: 539997's board of directors are considered experienced (8.4 years average tenure).

Kwality Pharmaceuticals Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Less than half of directors are independent

Kwality Pharmaceuticals Limited Announces the Resignation of Sachin Seth as Non- Executive and Non Independent Director

Less than half of directors are independent

CFO & Whole Time Director recently bought ₹1.3m worth of stock

Recent updates

Investor sentiment improves as stock rises 17%

Third quarter 2024 earnings released: EPS: ₹7.39 (vs ₹6.82 in 3Q 2023)

Insufficient new directors

Kwality Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 06, 2024

Kwality Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 04, 2023

Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

First quarter 2024 earnings released: EPS: ₹5.10 (vs ₹9.99 in 1Q 2023)

Kwality Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 10, 2023

New minor risk - Share price stability

Full year 2023 earnings released: EPS: ₹18.16 (vs ₹116 in FY 2022)

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: EPS: ₹6.82 (vs ₹15.20 in 3Q 2022)

Investor sentiment improved over the past week

Less than half of directors are independent

Kwality Pharmaceuticals Limited Announces the Resignation of Sachin Seth as Non- Executive and Non Independent Director

Second quarter 2023 earnings released: EPS: ₹8.82 (vs ₹57.33 in 2Q 2022)

Investor sentiment improved over the past week

Kwality Pharmaceuticals Limited to Report Fiscal Year 2023 Results on May 30, 2023

Investor sentiment improved over the past week

First quarter 2023 earnings released

Kwality Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 13, 2022

Kwality Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023

Investor sentiment improved over the past week

Kwality Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 28, 2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

CFO & Whole Time Director recently bought ₹1.3m worth of stock

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First half 2022 earnings released: EPS ₹90.57 (vs ₹6.70 in 1H 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹14.60 (vs ₹8.02 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day high: ₹61.15

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: ₹49.00

Kwality Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 13, 2020

Kwality Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2020

Kwality Pharmaceuticals Limited to Report Second Half, 2020 Results on Jul 13, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age